Please login to the form below

Not currently logged in
Email:
Password:

Astellas adds to US comms team

Marty Golden appointed VP, government affairs

Astellas continued to strengthen its communication and public affairs efforts in the US with the appointment of Marty Golden as VP, government affairs.

In this role, Golden will lead federal government affairs, state government affairs, therapeutic area government strategy, and corporate government strategy for Astellas in the Americas.

The appointment comes just days after Astellas announced the appointment of PhRMA's Karl Uhlendorf as communications and advocacy director.

Both additions are part of a commitment by Astellas to build its' US corporate communications tams. Other recent appointments include former Lilly comms chief Jeff Winton as senior VP, chief communications officer.

Golden has been with Astellas since 2006 and most recently served as VP, hospital and transplant sales.

Prior to joining Astellas, Golden held a number of positions with increasing responsibility across several disciplines for Novartis, Johnson & Johnson and Bristol-Myers Squibb.

30th June 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics